Animal models to study links between cardiovascular disease and renal failure and their relevance to human pathology

Frontiers in Immunology

Volumn 6, Issue SEP, 2015, Pages

  Hewitson, Tim D ^a,b   Holt, Stephen G ^a,b   Smith, Edward R ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Animal models; Cardiorenal syndrome; Heart; Kidney; Review

Indexed keywords

INTERLEUKIN 6; NITRIC OXIDE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE; LIVER DISEASE; LUPUS VULGARIS; NONHUMAN; OBESITY; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

EID: 84946561497     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00465     Document Type: Review

References (103)

1. Tomlinson LA, Holt SG. Is the kidney just a modified blood vessel? Unravelling the direction of causality between cardiovascular and renal disease. Atherosclerosis (2011) 216(2):275-6. doi: 10.1016/j.atherosclerosis.2011.02.049.
2. Liu S, Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H. Cardiorenal syndrome: pathophysiology, preclinical models, management and potential role of uraemic toxins. Clin Exp Pharmacol Physiol (2012) 39(8):692-700. doi:10.1111/j.1440-1681.2011.05632.x.
3. Szymanski MK, de Boer RA, Navis GJ, van Gilst WH, Hillege HL. Animal models of cardiorenal syndrome: a review. Heart Fail Rev (2012) 17(3):411-20. doi:10.1007/s10741-011-9279-6.
4. Bongartz LG, Braam B, Gaillard CA, Cramer MJ, Goldschmeding R, Verhaar MC, et al. Target organ cross talk in cardiorenal syndrome: animal models. Am J Physiol Renal Physiol (2012) 303(9):F1253-63. doi:10.1152/ajprenal.00392.2012.
5. Tsuruya K, Eriguchi M. Cardiorenal syndrome in chronic kidney disease. Curr Opin Nephrol Hypertens (2015) 24(2):154-62. doi:10.1097/MNH.0000000000000099.
6. El-Atat FA, Stas SN, McFarlane SI, Sowers JR. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol (2004) 15(11):2816-27. doi:10.1097/01.ASN.0000133698.80390.37.
7. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol (2008) 52(19):1527-39. doi:10.1016/j.jacc.2008.07.051.
8. McCullough PA, Haapio M, Mankad S, Zamperetti N, Massie B, Bellomo R, et al. Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI consensus conference. Nephrol Dial Transplant (2010) 25(6):1777-84. doi:10.1093/ndt/gfq180.
9. Hatamizadeh P, Fonarow GC, BudoffMJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K. Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol (2013) 9(2):99-111. doi:10.1038/nrneph.2012.279.
10. Braam B, Joles JA, Danishwar AH, Gaillard CA. Cardiorenal syndrome-current understanding and future perspectives. Nat Rev Nephrol (2014) 10(1):48-55. doi:10.1038/nrneph.2013.250.
11. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation (2010) 121(23):2592-600. doi:10.1161/CIRCULATIONAHA.109.886473.
12. Kumar S, Bogle R, Banerjee D. Why do young people with chronic kidney disease die early? World J Nephrol (2014) 3(4):143-55. doi:10.5527/wjn.v3.i4.143.
13. Lekawanvijit S, Kompa AR, Zhang Y, Wang BH, Kelly DJ, Krum H. Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndrome. Am J Physiol Heart Circ Physiol (2012) 302(9):H1884-93. doi:10.1152/ajpheart.00967.2011.
14. Samuel CS, Bodaragama H, Chew JY, Widdop RE, Royce SG, Hewitson TD. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease. Hypertension (2014) 64(2):315-22. doi:10.1161/HYPERTENSIONAHA.114.03594.
15. Peti-Peterdi J, Harris RC. Macula densa sensing and signaling mechanisms of renin release. J Am Soc Nephrol (2010) 21(7):1093-6. doi:10.1681/ASN.2009070759.
16. Noma T, Nishiyama A, Mizushige K, Murakami K, Tsuji T, Kohno M, et al. Possible role of uncoupling protein in regulation of myocardial energy metabolism in aortic regurgitation model rats. FASEB J (2001) 15(7):1206-8.
17. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, et al. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation (2012) 125(11):1402-13. doi:10.1161/CIRCULATIONAHA.111.064097.
18. Doty JM, Saggi BH, Sugerman HJ, Blocher CR, Pin R, Fakhry I, et al. Effect of increased renal venous pressure on renal function. J Trauma (1999) 47(6):1000-3. doi:10.1097/00005373-199907000-00076.
19. Hewitson TD. Fibrosis in the kidney: is a problem shared a problem halved? Fibrogenesis Tissue Repair (2012) 5(Suppl 1):S14. doi:10.1186/1755-1536-5-S1-S14.
20. Bursac N. Cardiac fibroblasts in pressure overload hypertrophy: the enemy within? J Clin Invest (2014) 124(7):2850-3. doi:10.1172/JCI76628.
21. Hewitson TD, Ono T, Becker GJ. Small animal models of kidney disease: a review. Methods Mol Biol (2009) 466:41-57. doi:10.1007/978-1-59745-352-3_4.
22. Rambausek M, Ritz E, Mall G, Mehls O, Katus H. Myocardial hypertrophy in rats with renal insufficiency. Kidney Int (1985) 28(5):775-82. doi:10.1038/ki.1985.197.
23. Stefanski A, Schmidt KG, Waldherr R, Ritz E. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int (1996) 50(4):1321-6. doi:10.1038/ki.1996.444.
24. Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Langham RG, Nishijima F, et al. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One (2012) 7(7):e41281. doi:10.1371/journal.pone.0041281.
25. Suzuki H, Schaefer L, Ling H, Schaefer RM, Dammrich J, Teschner M, et al. Prevention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE inhibitor administration: potential role of lysosomal proteinases. Am J Nephrol (1995) 15(2):129-36. doi:10.1159/000168817.
26. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G. Reduced capillary density in the myocardium of uremic rats-a stereological study. Kidney Int (1992) 42(5):1079-85. doi:10.1038/ki.1992.390.
27. Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney Int Suppl (2005) 99:S25-9. doi:10.1111/j.1523-1755.2005.09906.x.
28. Mettler FP, Young DM, Ward JM. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res (1977) 37(8 Pt 1):2705-13.
29. Noiri E, Nagano N, Negishi K, Doi K, Miyata S, Abe M, et al. Efficacy of darbepoetin in doxorubicin-induced cardiorenal injury in rats. Nephron Exp Nephrol (2006) 104(1):e6-14. doi:10.1159/000093258.
30. van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol (2005) 46(1):125-33. doi:10.1016/j.jacc.2005.03.044.
31. Zebrack JS, Anderson JL, Beddhu S, Horne BD, Bair TL, Cheung A, et al. Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J Am Coll Cardiol (2003) 42(1):57-63. doi:10.1016/S0735-1097(03)00564-3.
32. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med (1990) 323(4):236-41. doi:10.1056/NEJM199007263230405.
33. Kelly KJ. Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol (2003) 14(6):1549-58. doi:10.1097/01.ASN.0000064946.94590.46.
34. Yamada S, Tokumoto M, Tatsumoto N, Taniguchi M, Noguchi H, Nakano T, et al. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia. Am J Physiol Renal Physiol (2014) 306(12):F1418-28. doi:10.1152/ajprenal.00633.2013.
35. Cho E, Kim M, Ko YS, Lee HY, Song M, Kim MG, et al. Role of inflammation in the pathogenesis of cardiorenal syndrome in a rat myocardial infarction model. Nephrol Dial Transplant (2013) 28(11):2766-78. doi:10.1093/ndt/gft376.
36. Chang A, Ko K, Clark MR. The emerging role of the inflammasome in kidney diseases. Curr Opin Nephrol Hypertens (2014) 23(3):204-10. doi:10.1097/01.mnh.0000444814.49755.90.
37. Fiore MC, Jimenez PM, Cremonezzi D, Juncos LI, Garcia NH. Statins reverse renal inflammation and endothelial dysfunction induced by chronic high salt intake. Am J Physiol Renal Physiol (2011) 301(2):F263-70. doi:10.1152/ajprenal.00109.2010.
38. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant (1996) 11(12):2449-52. doi:10.1093/oxfordjournals.ndt.a027213.
39. Bongartz LG, Braam B, Verhaar MC, Cramer MJ, Goldschmeding R, Gaillard CA, et al. Transient nitric oxide reduction induces permanent cardiac systolic dysfunction and worsens kidney damage in rats with chronic kidney disease. Am J Physiol Regul Integr Comp Physiol (2010) 298(3):R815-23. doi:10.1152/ajpregu.00727.2009.
40. Eriguchi M, Tsuruya K, Haruyama N, Yamada S, Tanaka S, Suehiro T, et al. Renal denervation has blood pressure-independent protective effects on kidney and heart in a rat model of chronic kidney disease. Kidney Int (2015) 87(1):116-27. doi:10.1038/ki.2014.220.
41. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol (2003) 41(12):2164-71. doi:10.1016/S0735-1097(03)00471-6.
42. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int (2003) 63(1):179-85. doi:10.1046/j.1523-1755.2003.00702.x.
43. Kielstein JT, Bode-Boger SM, Klein G, Graf S, Haller H, Fliser D. Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest (2003) 33(5):370-5. doi:10.1046/j.1365-2362.2003.01149.x.
44. Onuigbo MA. RAAS inhibition and cardiorenal syndrome. Curr Hypertens Rev (2014) 10(2):107-11. doi:10.2174/1573402111666141231144228.
45. Guo P, Nishiyama A, Rahman M, Nagai Y, Noma T, Namba T, et al. Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade. J Hypertens (2006) 24(6):1097-104. doi:10.1097/01.hjh.0000226200.73065.5d.
46. Taylor D, Bhandari S, Seymour AM. Mitochondrial dysfunction in uremic cardiomyopathy. Am J Physiol Renal Physiol (2015) 308(6):F579-87. doi:10.1152/ajprenal.00442.2014.
47. Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H. Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circ Res (2012) 111(11):1470-83. doi:10.1161/CIRCRESAHA.112.278457.
48. Yang K, Xu X, Nie L, Xiao T, Guan X, He T, et al. Indoxyl sulfate induces oxidative stress and hypertrophy in cardiomyocytes by inhibiting the AMPK/UCP2 signaling pathway. Toxicol Lett (2015) 234(2):110-9. doi:10.1016/j.toxlet.2015.01.021.
49. Yisireyili M, Shimizu H, Saito S, Enomoto A, Nishijima F, Niwa T. Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats. Life Sci (2013) 92(24-26):1180-5. doi:10.1016/j.lfs.2013.05.008.
50. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis (1995) 26(5):861-5. doi:10.1016/0272-6386(95)90456-5.
51. Jacob F, Clark LA, Guzman PA, Osborn JW. Role of renal nerves in development of hypertension in DOCA-salt model in rats: a telemetric approach. Am J Physiol Heart Circ Physiol (2005) 289(4):H1519-29. doi:10.1152/ajpheart.00206.2005.
52. KDIGO CKD-MBD workgroup. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2009) 113:S1-130. doi:10.1038/ki.2009.188.
53. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med (2000) 342(20):1478-83. doi:10.1056/NEJM200005183422003.
54. London GM, Marchais SJ, Guerin AP, Metivier F, Pannier B. Cardiac hypertrophy and arterial alterations in end-stage renal disease: hemodynamic factors. Kidney Int Suppl (1993) 41:S42-9.
55. Briet M, Boutouyrie P, Laurent S, London GM. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int (2012) 82(4):388-400. doi:10.1038/ki.2012.131.
56. Mitchell GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol (1985) (2008) 105(5):1652-60. doi:10.1152/japplphysiol.90549.2008.
57. Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol (2007) 2(6):1241-8. doi:10.2215/CJN.02190507.
58. Ng K, Hildreth CM, Phillips JK, Avolio AP. Aortic stiffness is associated with vascular calcification and remodeling in a chronic kidney disease rat model. Am J Physiol Renal Physiol (2011) 300(6):F1431-6. doi:10.1152/ajprenal.00079.2011.
59. SutliffRL, Walp ER, El-Ali AM, Elkhatib S, Lomashvili KA, O'Neill WC. Effect of medial calcification on vascular function in uremia. Am J Physiol Renal Physiol (2011) 301(1):F78-83. doi:10.1152/ajprenal.00533.2010.
60. Ejerblad S, Eriksson I, Johansson H. Uraemic arterial disease. An experimental study with special reference to the effect of parathyroidectomy. Scand J Urol Nephrol (1979) 13(2):161-9. doi:10.3109/00365597909181172.
61. Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int (2003) 64(2):441-50. doi:10.1046/j.1523-1755.2003.00126.x.
62. Gagnon RF, Duguid WP. A reproducible model for chronic renal failure in the mouse. Urol Res (1983) 11(1):11-4. doi:10.1007/BF00272702.
63. Shobeiri N, Adams MA, Holden RM. Vascular calcification in animal models of CKD: a review. Am J Nephrol (2010) 31(6):471-81. doi:10.1159/000299794.
64. Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int (2014) 85(1):142-50. doi:10.1038/ki.2013.271.
65. Tamagaki K, Yuan Q, Ohkawa H, Imazeki I, Moriguchi Y, Imai N, et al. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrol Dial Transplant (2006) 21(3):651-9. doi:10.1093/ndt/gfi273.
66. Ferrari GO, Ferreira JC, Cavallari RT, Neves KR, dos Reis LM, Dominguez WV, et al. Mineral bone disorder in chronic kidney disease: head-to-head comparison of the 5/6 nephrectomy and adenine models. BMC Nephrol (2014) 15:69. doi:10.1186/1471-2369-15-69.
67. Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, Chen X, et al. A rat model of chronic kidney disease-mineral bone disorder. Kidney Int (2009) 75(2):176-84. doi:10.1038/ki.2008.456.
68. Stubbs JR, He N, Idiculla A, Gillihan R, Liu S, David V, et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res (2012) 27(1):38-46. doi:10.1002/jbmr.516.
69. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol (2010) 7(9):528-36. doi:10.1038/nrcardio.2010.115.
70. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/-mice. Arterioscler Thromb Vasc Biol (2007) 27(12):2589-96. doi:10.1161/ATVBAHA.107.153668.
71. Bobryshev YV. Transdifferentiation of smooth muscle cells into chondrocytes in atherosclerotic arteries in situ: implications for diffuse intimal calcification. J Pathol (2005) 205(5):641-50. doi:10.1002/path.1743.
72. Neven E, Dauwe S, De Broe ME, D'Haese PC, Persy V. Endochondral bone formation is involved in media calcification in rats and in men. Kidney Int (2007) 72(5):574-81. doi:10.1038/sj.ki.5002353.
73. Davies MR, Lund RJ, Hruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol (2003) 14(6):1559-67. doi:10.1097/01.ASN.0000068404.57780.DD.
74. Speer MY, Yang HY, Brabb T, Leaf E, Look A, Lin WL, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res (2009) 104(6):733-41. doi:10.1161/CIRCRESAHA.108.183053.
75. Jahnen-Dechent W, Heiss A, Schafer C, Ketteler M. Fetuin-A regulation of calcified matrix metabolism. Circ Res (2011) 108(12):1494-509. doi:10.1161/CIRCRESAHA.110.234260.
76. Keutel J, Jorgensen G, Gabriel P. [A new autosomal-recessive hereditary syndrome. Multiple peripheral pulmonary stenosis, brachytelephalangia, inner-ear deafness, ossification or calcification of cartilages]. Dtsch Med Wochenschr (1971) 96(43):1676-1681assim. doi:10.1055/s-0028-1110200.
77. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Hohne W, et al. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet (2003) 34(4):379-81. doi:10.1038/ng1221.
78. Sakamoto M, Hosoda Y, Kojimahara K, Yamazaki T, Yoshimura Y. Arthritis and ankylosis in twy mice with hereditary multiple osteochondral lesions: with special reference to calcium deposition. Pathol Int (1994) 44(6):420-7. doi:10.1111/j.1440-1827.1994.tb01705.x.
79. ShroffRC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol (2010) 21(1):103-12. doi:10.1681/ASN.2009060640.
80. Yoshida H, Yokoyama K, Yaginuma T, Ohkido I, Yamamoto H, Utsunomiya Y, et al. Difference in coronary artery intima and media calcification in autopsied patients with chronic kidney disease. Clin Nephrol (2011) 75(1):1-7.
81. O'Neill WC, Adams AL. Breast arterial calcification in chronic kidney disease: absence of smooth muscle apoptosis and osteogenic transdifferentiation. Kidney Int (2013) 85(3):668-76. doi:10.1038/ki.2013.351.
82. Pinto YM, Paul M, Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res (1998) 39(1):77-88. doi:10.1016/S0008-6363(98)00077-7.
83. Ooshima A, Yamori Y, Okamoto K. Cardiovascular lesions in the selectively-bred group of spontaneously hypertensive rats with severe hypertension. Jpn Circ J (1972) 36(8):797-812. doi:10.1253/jcj.36.797.
84. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, et al. Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol (2004) 15(6):1530-6. doi:10.1097/01.ASN.0000130154.42061.C6.
85. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int (1998) 54(2):343-52. doi:10.1046/j.1523-1755.1998.00019.x.
86. Samuel CS, Hewitson TD, Zhang Y, Kelly DJ. Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. Endocrinology (2008) 149(7):3286-93. doi:10.1210/en.2008-0250.
87. Lian M, Hewitson TD, Wigg B, Samuel CS, Chow F, Becker GJ. Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease. Nephrol Dial Transplant (2012) 27:906-12. doi:10.1093/ndt/gfr495.
88. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes (2004) 53(7):1813-23. doi:10.2337/diabetes.53.7.1813.
89. Joshi D, Gupta R, Dubey A, Shiwalkar A, Pathak P, Gupta RC, et al. TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. J Cardiovasc Pharmacol (2009) 54(1):72-81. doi:10.1097/FJC.0b013e3181ac3a34.
90. Hayden MR, Sowers JR. Childhood-adolescent obesity in the cardiorenal syndrome: lessons from animal models. Cardiorenal Med (2011) 1(2):75-86. doi:10.1159/000327022.
91. Sen S, Chen S, Feng B, Iglarz M, Chakrabarti S. Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist. Life Sci (2012) 91(13-14):658-68. doi:10.1016/j.lfs.2012.03.032.
92. Bomzon A, Holt S, Moore K. Bile acids, oxidative stress, and renal function in biliary obstruction. Semin Nephrol (1997) 17(6):549-62.
93. Tajuddin M, Tariq M, Bilgrami NL, Kumar S. Biochemical and pathological changes in the heart following bile duct ligation. Adv Myocardiol (1980) 2:209-12.
94. Suzuki K, Nakagawa K, Yamamoto T, Miyazawa T, Kimura F, Kamei M, et al. Carbon tetrachloride-induced hepatic and renal damages in rat: inhibitory effects of cacao polyphenol. Biosci Biotechnol Biochem (2015) 79(10):1669-75. doi:10.1080/09168451.2015.1039481.
95. Liu Y, Meyer C, Xu C, Weng H, Hellerbrand C, ten Dijke P, et al. Animal models of chronic liver diseases. Am J Physiol Gastrointest Liver Physiol (2013) 304(5):G449-68. doi:10.1152/ajpgi.00199.2012.
96. Perry D, Sang A, Yin Y, Zheng YY, Morel L. Murine models of systemic lupus erythematosus. J Biomed Biotechnol (2011) 2011:271694. doi:10.1155/2011/271694.
97. Pansky B, Freimer EH. Spontaneous carditis in the NZB mouse and its hybrids. Arthritis Rheum (1974) 17(4):403-8. doi:10.1002/art.1780170410.
98. Huston DP, Steinberg AD. Animal models of human systemic lupus erythematosus. Yale J Biol Med (1979) 52(3):289-305.
99. Sharabi A, Dayan M, Zinger H, Mozes E. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide. J Clin Immunol (2010) 30(1):34-44. doi:10.1007/s10875-009-9326-4.
100. Liu S, Kompa AR, Kumfu S, Nishijima F, Kelly DJ, Krum H, et al. Subtotal nephrectomy accelerates pathological cardiac remodeling post-myocardial infarction: implications for cardiorenal syndrome. Int J Cardiol (2013) 168(3):1866-80. doi:10.1016/j.ijcard.2012.12.065.
101. Windt WA, Henning RH, Kluppel AC, Xu Y, de Zeeuw D, van Dokkum RP. Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats. Nephrol Dial Transplant (2008) 23(10):3103-10. doi:10.1093/ndt/gfn233.
102. Bongartz LG, Joles JA, Verhaar MC, Cramer MJ, Goldschmeding R, Tilburgs C, et al. Subtotal nephrectomy plus coronary ligation leads to more pronounced damage in both organs than either nephrectomy or coronary ligation. Am J Physiol Heart Circ Physiol (2012) 302(3):H845-54. doi:10.1152/ajpheart.00261.2011.
103. van Dokkum RP, Eijkelkamp WB, Kluppel AC, Henning RH, van Goor H, Citgez M, et al. Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol (2004) 15(12):3103-10. doi:10.1097/01.ASN.0000145895.62896.98.